Multiple Sclerosis Trial, Recruiting
Who may be able to join
AI generated eligibility summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI
Who might be able to join this trial:
- You must be willing to sign a consent form agreeing to take part in the study
- You must be between 55 and 80 years old
- You must have been diagnosed with relapsing multiple sclerosis (a type of MS that comes and goes in episodes) based on specific recognised diagnostic guidelines from 2017
- You must be about to start, or have recently started (within the last 6 months), a medication called ublituximab as prescribed by your doctor
Who may not be able to join:
- You are currently taking part in another clinical trial that involves a treatment or intervention for MS
- You received your first dose of ublituximab more than 6 months before joining this study
- You have previously had a severe, life-threatening reaction during an infusion of any medication belonging to the same family as ublituximab (known as anti-CD20 therapies)
- You have a significant ongoing or long-term viral, bacterial, or fungal infection that requires extended treatment, or you have had repeated infections in the 6 to 12 months before starting ublituximab (confirm with trial site)
Important: Always verify eligibility with the trial site directly before applying.
Based on publicly available eligibility criteria from ClinicalTrials.gov. Verify directly with the trial site before acting. This is not medical advice.
Contact this trial
Phone: 781-551-5812
Contact details sourced from ClinicalTrials.gov. Verify directly with the trial site before attending.
GP referral letter
Print a one-page summary to share with your doctor.
Trial details
Where this trial is recruiting
Primary endpoints
Incidence of infection (including UTI and other active acute, opportunistic and/or chronic infection); Incidence of treatment-emergent adverse events (TEAEs)/serious adverse events (SAEs)
Can't join this trial?
Data last synced from ClinicalTrials.gov: 7 July 2026. Trial status can change. Always verify current status directly with the trial site before making any decision.